|  |  |  | |
| | MedWorm: Genital Herpes | | |
| | | | |
| | | | |
| |
|
| CONCLUSIONS/SIGNIFICANCE: In this first use of HIV-1 sequencing to establish endpoints in a large clinical trial, more than one-fourth of transmissions were unlinked to the enrolled partner, illustrating the relevance of these methods in the design of future HIV-1 prevention trials in serodiscordant couples. A hierarchy of sequencing techniques, analysis methods, and expert adjudication contributed to the linkage determination process. PMID: 21399681 [PubMed - as supplied by publisher] (Source: Herpes) |
| |
| | |
| |
| | | | |
| | | | |
| |
|
Authors: Halford WP, Püschel R, Gershburg E, Wilber A, Gershburg S, Rakowski B Glycoprotein D (gD-2) is the entry receptor of herpes simplex virus 2 (HSV-2), and is the immunogen in the pharmaceutical industry's lead HSV-2 vaccine candidate. Efforts to prevent genital herpes using gD-2 subunit vaccines have been ongoing for 20 years at a cost in excess of $100 million. To date, gD-2 vaccines have yielded equivocal protection in clinical trials. Therefore, using a small animal model, we sought to determine if a live-attenuated HSV-2 ICP0(-) virus would elicit better protection against genital herpes than a gD-2 subunit vaccine. Mice immunized with gD-2 and a potent adjuvant (alum+monophosphoryl lipid A) produced high titers of gD-2 antibody. While gD-2-immunized mice possessed signific...
MedWorm Sponsor Message: Watch the new MedWorm demo and find out how to get all the very latest, relevant, organized information daily! |
| |
| | |
| |
| | | | |
| | | | |
| |
|
| We examined correlates of genital HIV-1 RNA in women who were seropositive for both herpes simplex virus (HSV)-2 and HIV-1 and who were enrolled in a randomised controlled trial of HSV suppressive therapy (aciclovir 400 mg b.i.d vs. placebo) in Tanzania. PMID: 21390251 [PubMed - in process] (Source: Herpes) |
| |
| | |
| |
|  | |  | |
|
